The information on this page is intended for healthcare professionals. Some of the products and services shown here may not be available in your country or region.
Mar. 19, 2022

Master Class Webinar: Optimal Strategies for Stent Implantation

The clinical data from this investigator-initiated MASTER DAPT (MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen) study demonstrates that one month of DAPT was non-inferior to treatment continuation for at least 2 additional months for the occurrence of net and major adverse clinical events, and reduced major or clinically relevant non-major bleeding.

We held a MASTER DAPT webinar for the Asia-Pacific, during which experts from across the region fielded questions on Dual Antiplatelet Therapy (DAPT) management for High Bleeding Risk (HBR) patients. More details are available below.

*MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and a data management group (CERC, Paris, France; Cardialysis, Rotterdam, The Netherlands; CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).